Insmed Incorporated (INSM) Receives Average Recommendation of “Buy” from Brokerages

Share on StockTwits

Insmed Incorporated (NASDAQ:INSM) has been given an average recommendation of “Buy” by the ten analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $37.00.

Several brokerages recently commented on INSM. Canaccord Genuity set a $44.00 price target on shares of Insmed and gave the stock a “buy” rating in a research report on Friday, March 8th. BidaskClub raised shares of Insmed from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. ValuEngine lowered shares of Insmed from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. JMP Securities raised shares of Insmed from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a research report on Friday, February 15th. Finally, Goldman Sachs Group raised shares of Insmed from a “neutral” rating to a “buy” rating and upped their price target for the stock from $29.00 to $35.00 in a research report on Thursday, January 17th.

Shares of INSM stock opened at $28.21 on Friday. Insmed has a one year low of $11.31 and a one year high of $31.58. The company has a quick ratio of 6.42, a current ratio of 6.51 and a debt-to-equity ratio of 1.52. The company has a market cap of $2.26 billion, a P/E ratio of -6.76 and a beta of 3.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Friday, February 22nd. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $9.84 million for the quarter, compared to analysts’ expectations of $5.01 million. Research analysts anticipate that Insmed will post -3.83 EPS for the current year.

In other news, Director Donald J. Hayden, Jr. sold 14,900 shares of the stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $28.08, for a total value of $418,392.00. Following the completion of the sale, the director now owns 77,097 shares of the company’s stock, valued at $2,164,883.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alfred Altomari sold 5,500 shares of the stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $25.00, for a total transaction of $137,500.00. Following the completion of the sale, the director now directly owns 36,942 shares of the company’s stock, valued at approximately $923,550. The disclosure for this sale can be found here. Insiders sold 36,900 shares of company stock valued at $995,892 in the last three months. Company insiders own 3.88% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Insmed by 0.5% in the third quarter. FMR LLC now owns 11,556,128 shares of the biopharmaceutical company’s stock worth $233,666,000 after acquiring an additional 62,658 shares in the last quarter. Vanguard Group Inc increased its position in shares of Insmed by 2.3% in the third quarter. Vanguard Group Inc now owns 6,802,706 shares of the biopharmaceutical company’s stock worth $137,551,000 after acquiring an additional 154,130 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Insmed by 2.3% in the third quarter. Vanguard Group Inc. now owns 6,802,706 shares of the biopharmaceutical company’s stock worth $137,551,000 after acquiring an additional 154,130 shares in the last quarter. Foresite Capital Management IV LLC increased its position in shares of Insmed by 9.8% in the fourth quarter. Foresite Capital Management IV LLC now owns 1,977,236 shares of the biopharmaceutical company’s stock worth $25,941,000 after acquiring an additional 176,649 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its stake in shares of Insmed by 164.6% in the third quarter. Baker BROS. Advisors LP now owns 1,851,982 shares of the biopharmaceutical company’s stock valued at $37,447,000 after purchasing an additional 1,151,982 shares during the period.

Insmed Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company's product candidate is ARIKAYCE for the treatment of mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting.

Featured Story: What is the S&P 500 Index?

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vanguard S&P 500 ETF  Shares Sold by Waller Financial Planning Group Inc.
Vanguard S&P 500 ETF Shares Sold by Waller Financial Planning Group Inc.
Waller Financial Planning Group Inc. Reduces Position in Vanguard Mid-Cap ETF
Waller Financial Planning Group Inc. Reduces Position in Vanguard Mid-Cap ETF
Eaton Co. PLC  Position Cut by Beacon Financial Group
Eaton Co. PLC Position Cut by Beacon Financial Group
Beacon Financial Group Has $2.19 Million Holdings in Anheuser Busch Inbev NV
Beacon Financial Group Has $2.19 Million Holdings in Anheuser Busch Inbev NV
Beacon Financial Group Has $888,000 Position in Omnicom Group Inc.
Beacon Financial Group Has $888,000 Position in Omnicom Group Inc.
Bfsg LLC Purchases Shares of 14,813 Synchrony Financial
Bfsg LLC Purchases Shares of 14,813 Synchrony Financial


© 2006-2019 Ticker Report